| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-066393 |
| cik | 2012593 |
| name | RAPPORT THERAPEUTICS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | MA |
| cityba | BOSTON |
| zipba | 02215 |
| bas1 | 1325 BOYLSTON STREET |
| bas2 | SUITE 401 |
| baph | 857-321-8020 |
| countryma | US |
| stprma | MA |
| cityma | BOSTON |
| zipma | 02215 |
| mas1 | 1325 BOYLSTON STREET |
| mas2 | SUITE 401 |
| countryinc | US |
| stprinc | DE |
| ein | 880724208 |
| former | |
| changed | |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 07:30:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | rapp-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-066393 | 20241231 | Accounts Payable Current | 1954000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Additional Paid In Capital Common Stock | 433702000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1491000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1491000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-066393 | 20250331 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20231231 | Common Stock Shares Outstanding | 4170817.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20250331 | Comprehensive Income Net Of Tax | -23636000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Deferred Offering Costs | 1472000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | General And Administrative Expense | 328000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Facility Related And Other; | ||
| 0000950170-25-066393 | 20250331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 331000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Increase Decrease In Operating Lease Liabilities | 73000.0000 | USD | 1 | 0000950170-25-066393 | |||
| 0000950170-25-066393 | 20240331 | Investment Income Interest | 1815000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Liabilities Current | 8767000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Nonoperating Income Expense | -5575000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20230831 | Proceeds From Issuance Of Convertible Preferred Stock | 8000000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock Early Exercised; Type Of Arrangement= Series B Milestone Tranches; | ||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 3934000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Preclinical Programs External Expenses; | ||
| 0000950170-25-066393 | 20250331 | Restricted Cash Current | 105000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Retained Earnings Accumulated Deficit | -147808000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Stockholders Equity | -68107000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20241231 | Stockholders Equity | 37000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20250331 | Stockholders Equity | -95000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 6000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 6000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20231231 | Temporary Equity Carrying Amount Attributable To Parent | 89487000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20231231 | Accrued Liabilities Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20250331 | Accrued Liabilities Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Janssen Pharmaceutical Nv; | ||
| 0000950170-25-066393 | 20240331 | Cash And Cash Equivalents At Carrying Value | 74267000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Cash And Cash Equivalents At Carrying Value | 56805000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 74372000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Common Stock Shares Outstanding | 36497434.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20240331 | Comprehensive Income Net Of Tax | -22833000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | General And Administrative Expense | 4590000.0000 | USD | 1 | us-gaap/2024 | Includes related party amounts of zero and $0.1 million for the three months ended March 31, 2025 and 2024, respectively (see Note 10). | ||
| 0000950170-25-066393 | 20240331 | General And Administrative Expense | 1865000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Professional And Consulting Costs; | ||
| 0000950170-25-066393 | 20240331 | General And Administrative Expense | 100000.0000 | USD | 1 | us-gaap/2024 | Related Party Transaction= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20250331 | General And Administrative Expense | 4959000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= General And Administrative Personnel Related Costs Including Stock- Based Compensation; | ||
| 0000950170-25-066393 | 20250331 | Increase Decrease In Accounts Payable | 185000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Liabilities And Stockholders Equity | 314933000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Net Income Loss | -22669000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20250331 | Operating Expenses | 27108000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Operating Lease Liability Noncurrent | 739000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Operating Lease Right Of Use Asset | 7470000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Other Assets Noncurrent | 211000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240630 | Payments Of Stock Issuance Costs | 1300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= Private Placement; | ||
| 0000950170-25-066393 | 20250331 | Payments To Acquire Property Plant And Equipment | 291000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Stockholders Equity | -39633000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Stockholders Equity | -522000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20231231 | Temporary Equity Carrying Amount Attributable To Parent | 77091000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20241231 | Accrued Liabilities Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Janssen Pharmaceutical Nv; | ||
| 0000950170-25-066393 | 20250331 | Assets | 302053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 799000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Change In Fair Value Of Preferred Stock Tranche Right Liability | 7390000.0000 | USD | 1 | 0000950170-25-066393 | |||
| 0000950170-25-066393 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Deferred Offering Costs | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Depreciation Depletion And Amortization | 152000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Earnings Per Share Diluted | -11.0700 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | General And Administrative Expense | 913000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Facility Related And Other; | ||
| 0000950170-25-066393 | 20250331 | General And Administrative Expense | 0.0000 | USD | 1 | us-gaap/2024 | Related Party Transaction= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 2070000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Liabilities | 16217000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Oci Equity Method Investment After Tax Parent | 427000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Operating Lease Right Of Use Asset | 1442000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Other Assets Noncurrent | 160000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240630 | Payments Of Stock Issuance Costs | 15500000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= I P O; | ||
| 0000950170-25-066393 | 20231231 | Prepaid Expense And Other Assets Current | 1500000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Neuropace Agreement; | ||
| 0000950170-25-066393 | 20250331 | Prepaid Expense And Other Assets Current | 5481000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Profit Loss | -22669000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Property Plant And Equipment Net | 3404000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 4017000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Research And Development Personnel Related Costs Including Stock- Based Compensation; | ||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 100000.0000 | USD | 1 | us-gaap/2024 | Range= Maximum; Related Party Transaction= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20240331 | Settlement Of Series A Preferred Stock Tranche Right Liability | 11590000.0000 | USD | 1 | 0000950170-25-066393 | Class Of Stock= Series B Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Share Based Compensation | 4040000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Stockholders Equity | 433702000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 3240.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | 7343000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Temporary Equity Carrying Amount Attributable To Parent | 145252000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20231231 | Temporary Equity Shares Outstanding | 100182354.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Accounts Payable Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Janssen Pharmaceutical Nv; | ||
| 0000950170-25-066393 | 20240930 | Accrued Liabilities Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20250331 | Accrued Liabilities Current | 6236000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 70254000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Common Stock Shares Outstanding | 4170817.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20241231 | Common Stock Shares Outstanding | 36580202.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Earnings Per Share Basic | -11.0700 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Earnings Per Share Diluted | -0.6800 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 181000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Liabilities Current | 9383000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Net Cash Provided By Used In Financing Activities | 5000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Net Cash Provided By Used In Operating Activities | -17615000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Operating Expenses | 17094000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 427000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Payments Of Financing Costs | 283000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Proceeds From Issuance Of Convertible Preferred Stock | 64000000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; Type Of Arrangement= Series B Second Tranche Milestone; | ||
| 0000950170-25-066393 | 20250331 | Proceeds From Stock Options Exercised | 6000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Property Plant And Equipment Net | 3529000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Retained Earnings Accumulated Deficit | -123745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 6439000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | 7343000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20240331 | Temporary Equity Carrying Amount Attributable To Parent | 89487000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20240331 | Temporary Equity Shares Outstanding | 100182354.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 2046889.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 35266577.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -95000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Accounts Payable Current | 0.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Janssen Pharmaceutical Nv; | ||
| 0000950170-25-066393 | 20250331 | Accounts Payable Current | 2139000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Accretion Amortization Of Discounts And Premiums Investments | 978000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -522000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Additional Paid In Capital Common Stock | 429657000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 4040000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 57709000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Common Stock Shares Issued | 36497434.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Common Stock Shares Outstanding | 36580202.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20250331 | Common Stock Shares Outstanding | 36497434.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Common Stock Value | 37000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | General And Administrative Expense | 1664000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Professional And Consulting Costs; | ||
| 0000950170-25-066393 | 20250331 | Liabilities And Stockholders Equity | 302053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Net Income Loss | -24063000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Oci Equity Method Investment After Tax Parent | 427000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20250331 | Operating Income Loss | -27108000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Operating Lease Liability Current | 1008000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Operating Lease Liability Noncurrent | 6834000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Payments Of Stock Issuance Costs | 87000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 6786000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Research And Development Personnel Related Costs Including Stock- Based Compensation; | ||
| 0000950170-25-066393 | 20240331 | Share Based Compensation | 1491000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Short Term Investments | 227778000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20231231 | Stockholders Equity | -25634000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Stockholders Equity | -160000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20241231 | Stockholders Equity | 429657000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20241231 | Stockholders Equity | -123745000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20240331 | Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | 68161000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20240331 | Temporary Equity Shares Outstanding | 89431030.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Accretion Amortization Of Discounts And Premiums Investments | 436000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Accrued Liabilities Current | 6076000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 4040000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20241231 | Assets Current | 309802000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Assets Current | 290968000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 56910000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-066393 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240531 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20241231 | Deferred Offering Costs | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Earnings Per Share Basic | -0.6800 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Increase Decrease In Operating Lease Liabilities | 161000.0000 | USD | 1 | 0000950170-25-066393 | |||
| 0000950170-25-066393 | 20240331 | Increase Decrease In Other Operating Assets | -27000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 825000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Net Cash Provided By Used In Financing Activities | 63659000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Net Cash Provided By Used In Investing Activities | 21031000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Net Income Loss | -78300000.0000 | USD | 4 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | 847000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Oci Equity Method Investment After Tax Parent | -164000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Operating Lease Liability Current | 737000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 156000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 411000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Payments For Repurchase Of Unvested Restricted Common Stock | 1000.0000 | USD | 1 | 0000950170-25-066393 | |||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 3901000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= R A P219 Program External Expenses; | ||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 300000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Neuropace Agreement; | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 19572000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 500000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Neuropace Agreement; | ||
| 0000950170-25-066393 | 20231231 | Stockholders Equity | 4000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20240331 | Stockholders Equity | 4000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20241231 | Stockholders Equity | 305427000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 3240.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20250331 | Stock Repurchased During Period Value | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20231231 | Temporary Equity Shares Outstanding | 51273790.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20241231 | Assets | 314933000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Cash And Cash Equivalents At Carrying Value | 57604000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Common Stock Shares Issued | 36580202.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Common Stock Value | 37000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Depreciation Depletion And Amortization | 244000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | General And Administrative Expense | 2397000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= General And Administrative Personnel Related Costs Including Stock- Based Compensation; | ||
| 0000950170-25-066393 | 20240331 | Increase Decrease In Accounts Payable | -1134000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Net Income Loss | -24063000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20250331 | Nonoperating Income Expense | 3045000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Oci Equity Method Investment After Tax Parent | -164000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20240331 | Operating Income Loss | -17094000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Operating Lease Right Of Use Asset | 0.0000 | USD | 0 | us-gaap/2024 | Geographic Distribution= Office Space In Boston Massachusetts; | ||
| 0000950170-25-066393 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -164000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Payments To Acquire Investments | 44801000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Payments To Acquire Investments | 43235000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Proceeds From Sale Maturity And Collections Of Investments | 3947000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Proceeds From Sale Maturity And Collections Of Investments | 64557000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Stockholders Equity | 285836000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 652000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 1577000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 3246000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Preclinical Programs External Expenses; | ||
| 0000950170-25-066393 | 20231231 | Stockholders Equity | 19796000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20240331 | Stockholders Equity | 28630000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-066393 | 20250331 | Stock Repurchased During Period Shares | 86008.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 4118000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | General And Administrative Expense | 7536000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Increase Decrease In Other Operating Assets | 51000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Investment Income Interest | 3045000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Liabilities | 9506000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Net Cash Provided By Used In Investing Activities | -41926000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Net Cash Provided By Used In Operating Activities | -20237000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Net Income Loss | -22669000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Payments Of Stock Issuance Costs | 87000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; Range= Maximum; Type Of Arrangement= Series B Second Tranche Milestone; | ||
| 0000950170-25-066393 | 20240331 | Payments To Acquire Property Plant And Equipment | 1072000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Prepaid Expense And Other Assets Current | 4417000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Prepaid Expense And Other Assets Current | 300000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Neuropace Agreement Amended; | ||
| 0000950170-25-066393 | 20240331 | Proceeds From Issuance Of Convertible Preferred Stock | 63942000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Profit Loss | -24063000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Research And Development Expense | 12504000.0000 | USD | 1 | us-gaap/2024 | Includes related party amounts of zero and less than $0.1 million for the three months ended March 31, 2025 and 2024, respectively (see Note 10). | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 7963000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= R A P219 Program External Expenses; | ||
| 0000950170-25-066393 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Related Party Transaction= Third Rock Ventures L L C; | ||
| 0000950170-25-066393 | 20240331 | Restricted Cash Current | 105000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Restricted Cash Current | 105000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20241231 | Short Term Investments | 248475000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20231231 | Stockholders Equity | 4000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-066393 | 20231231 | Stockholders Equity | -45438000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20250331 | Stockholders Equity | 37000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-066393 | 20250331 | Stockholders Equity | -147808000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-066393 | 20240331 | Stock Issued During Period Shares Conversion Of Convertible Securities | 38157240.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0000950170-25-066393 | 20250331 | Stock Repurchased During Period Value | 1000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Temporary Equity Carrying Amount Attributable To Parent | 234739000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Temporary Equity Shares Outstanding | 189613384.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 2046889.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-066393 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 35266577.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Amount of increase in right-of-use asset obtained in exchange for operating lease liability. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Short-Term Investments | Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. |
| Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments | The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Payments To Acquire Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Investments | The cash outflow associated with the purchase of all investments (debt, security, other) during the period. |
| Restricted Cash Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Current | Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Temporary Equity Carrying Amount Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | I | C | Temporary Equity, Carrying Amount, Attributable to Parent | Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Oci Equity Method Investment After Tax Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Equity Method Investment, after Tax, Parent | Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI, attributable to parent. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Stock Issued During Period Shares Conversion Of Convertible Securities | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Conversion of Convertible Securities | Number of shares issued during the period as a result of the conversion of convertible securities. | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Increase Decrease In Other Operating Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets | Amount of increase (decrease) in operating assets classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Settlement Of Series A Preferred Stock Tranche Right Liability | 0000950170-25-066393 | 1 | 0 | monetary | D | C | Settlement of Series A Preferred Stock Tranche Right Liability | Settlement of series A preferred stock tranche right liability. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Payments Of Stock Issuance Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Stock Issuance Costs | The cash outflow for cost incurred directly with the issuance of an equity security. |
| Stock Repurchased During Period Value | us-gaap/2024 | 0 | 0 | monetary | D | D | Stock Repurchased During Period, Value | Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. |
| Payments For Repurchase Of Unvested Restricted Common Stock | 0000950170-25-066393 | 1 | 0 | monetary | D | C | Payments for Repurchase of Unvested Restricted Common Stock | Payments for repurchase of unvested restricted common stock. |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | Amount of increase (decrease) in accrued expenses, and obligations classified as other. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | us-gaap/2024 | 0 | 0 | monetary | D | D | Noncash or Part Noncash Acquisition, Fixed Assets Acquired | The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Proceeds From Issuance Of Convertible Preferred Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Convertible Preferred Stock | The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. |
| Stock Repurchased During Period Shares | us-gaap/2024 | 0 | 0 | shares | D | Stock Repurchased During Period, Shares | Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. | |
| Temporary Equity Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Temporary Equity, Shares Outstanding | The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. | |
| Increase Decrease In Operating Lease Liabilities | 0000950170-25-066393 | 1 | 0 | monetary | D | C | Increase (Decrease) in Operating Lease Liabilities | Increase (decrease) in operating lease liabilities. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Deferred Offering Costs | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Offering Costs | Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Change In Fair Value Of Preferred Stock Tranche Right Liability | 0000950170-25-066393 | 1 | 0 | monetary | D | D | Change in Fair Value of Preferred Stock Tranche Right Liability | Change in fair value of preferred stock tranche right liability. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Accretion (Amortization) of Discounts and Premiums, Investments | The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Investment Income Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Payments Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Financing Costs | The cash outflow for loan and debt issuance costs. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Proceeds From Sale Maturity And Collections Of Investments | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale, Maturity and Collection of Investments | The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-066393 | 2 | 7 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-066393 | 2 | 8 | BS | 0 | H | Short Term Investments | us-gaap/2024 | Short-term investments | 0 |
| 0000950170-25-066393 | 2 | 9 | BS | 0 | H | Restricted Cash Current | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-066393 | 2 | 10 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-066393 | 2 | 11 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-066393 | 2 | 12 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0000950170-25-066393 | 2 | 13 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right of use asset, net | 0 |
| 0000950170-25-066393 | 2 | 14 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets | 0 |
| 0000950170-25-066393 | 2 | 15 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-066393 | 2 | 18 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-066393 | 2 | 19 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-066393 | 2 | 20 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Operating lease liability | 0 |
| 0000950170-25-066393 | 2 | 21 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-066393 | 2 | 22 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liability, net of current portion | 0 |
| 0000950170-25-066393 | 2 | 23 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-066393 | 2 | 24 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 11) | 0 |
| 0000950170-25-066393 | 2 | 26 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.001 par value; 500,000,000 shares authorized at March 31, 2025 and December 31, 2024; 36,497,434 shares and 36,580,202 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0000950170-25-066393 | 2 | 27 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-066393 | 2 | 28 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0000950170-25-066393 | 2 | 29 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-066393 | 2 | 30 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-066393 | 2 | 31 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-066393 | 3 | 16 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-066393 | 3 | 17 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-066393 | 3 | 18 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-066393 | 3 | 19 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-066393 | 3 | 20 | BS | 1 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-066393 | 3 | 21 | BS | 1 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-066393 | 4 | 2 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-066393 | 4 | 3 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-066393 | 4 | 4 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-066393 | 4 | 5 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-066393 | 4 | 7 | IS | 0 | H | Investment Income Interest | us-gaap/2024 | Interest income | 0 |
| 0000950170-25-066393 | 4 | 8 | IS | 0 | H | Change In Fair Value Of Preferred Stock Tranche Right Liability | 0000950170-25-066393 | Change in fair value of preferred stock tranche right liability | 1 |
| 0000950170-25-066393 | 4 | 9 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income, net | 0 |
| 0000950170-25-066393 | 4 | 10 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-066393 | 4 | 11 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per share attributable to common stockholders, basic | 0 |
| 0000950170-25-066393 | 4 | 12 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per share attributable to common stockholders, diluted | 0 |
| 0000950170-25-066393 | 4 | 13 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average common shares outstanding, basic | 0 |
| 0000950170-25-066393 | 4 | 14 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average common shares outstanding, diluted | 0 |
| 0000950170-25-066393 | 4 | 16 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-066393 | 4 | 17 | IS | 0 | H | Oci Equity Method Investment After Tax Parent | us-gaap/2024 | Change in unrealized gains (losses) on investments, net of tax | 0 |
| 0000950170-25-066393 | 4 | 18 | IS | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Total other comprehensive income (loss) | 0 |
| 0000950170-25-066393 | 4 | 19 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive loss | 0 |
| 0000950170-25-066393 | 5 | 9 | IS | 1 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-066393 | 5 | 10 | IS | 1 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-066393 | 6 | 13 | EQ | 0 | H | Temporary Equity Carrying Amount Attributable To Parent | us-gaap/2024 | Convertible Preferred Stock, beginning balance | 0 |
| 0000950170-25-066393 | 6 | 14 | EQ | 0 | H | Temporary Equity Shares Outstanding | us-gaap/2024 | Convertible Preferred Stock, beginning balance, shares | 0 |
| 0000950170-25-066393 | 6 | 15 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0000950170-25-066393 | 6 | 16 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance, shares | 0 |
| 0000950170-25-066393 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | us-gaap/2024 | Issuance of Series B convertible preferred stock for the settlement of the tranche right liability, net of issuance costs | 0 |
| 0000950170-25-066393 | 6 | 18 | EQ | 0 | H | Stock Issued During Period Shares Conversion Of Convertible Securities | us-gaap/2024 | Issuance of Series B convertible preferred stock for the settlement of the tranche right liability, net of issuance costs, shares | 0 |
| 0000950170-25-066393 | 6 | 22 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0000950170-25-066393 | 6 | 23 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Issuance of common stock upon exercise of stock options | 0 |
| 0000950170-25-066393 | 6 | 24 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Issuance of common stock upon exercise of stock options, shares | 0 |
| 0000950170-25-066393 | 6 | 25 | EQ | 0 | H | Stock Repurchased During Period Value | us-gaap/2024 | Repurchase of unvested restricted common stock | 1 |
| 0000950170-25-066393 | 6 | 26 | EQ | 0 | H | Stock Repurchased During Period Shares | us-gaap/2024 | Repurchase of unvested restricted common stock, shares | 1 |
| 0000950170-25-066393 | 6 | 27 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-066393 | 6 | 28 | EQ | 0 | H | Oci Equity Method Investment After Tax Parent | us-gaap/2024 | Change in unrealized gain (loss) on investments, net of tax | 0 |
| 0000950170-25-066393 | 6 | 29 | EQ | 0 | H | Temporary Equity Carrying Amount Attributable To Parent | us-gaap/2024 | Convertible Preferred Stock, ending balance | 0 |
| 0000950170-25-066393 | 6 | 30 | EQ | 0 | H | Temporary Equity Shares Outstanding | us-gaap/2024 | Convertible Preferred Stock, ending balance, shares | 0 |
| 0000950170-25-066393 | 6 | 31 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0000950170-25-066393 | 6 | 32 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance, shares | 0 |
| 0000950170-25-066393 | 7 | 11 | EQ | 1 | H | Payments Of Stock Issuance Costs | us-gaap/2024 | Issuance costs | 0 |
| 0000950170-25-066393 | 8 | 10 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-066393 | 8 | 12 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0000950170-25-066393 | 8 | 13 | CF | 0 | H | Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | Net (accretion) and amortization of investments in marketable securities | 1 |
| 0000950170-25-066393 | 8 | 14 | CF | 0 | H | Change In Fair Value Of Preferred Stock Tranche Right Liability | 0000950170-25-066393 | Change in fair value of preferred stock tranche right liability | 0 |
| 0000950170-25-066393 | 8 | 15 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Non-cash lease expense | 0 |
| 0000950170-25-066393 | 8 | 16 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0000950170-25-066393 | 8 | 18 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0000950170-25-066393 | 8 | 19 | CF | 0 | H | Increase Decrease In Other Operating Assets | us-gaap/2024 | Other assets | 1 |
| 0000950170-25-066393 | 8 | 20 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-066393 | 8 | 21 | CF | 0 | H | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-066393 | 8 | 22 | CF | 0 | H | Increase Decrease In Operating Lease Liabilities | 0000950170-25-066393 | Operating lease liabilities | 1 |
| 0000950170-25-066393 | 8 | 23 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0000950170-25-066393 | 8 | 25 | CF | 0 | H | Payments To Acquire Investments | us-gaap/2024 | Purchases of short-term investments | 1 |
| 0000950170-25-066393 | 8 | 26 | CF | 0 | H | Proceeds From Sale Maturity And Collections Of Investments | us-gaap/2024 | Maturities of short-term investments | 0 |
| 0000950170-25-066393 | 8 | 27 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of property and equipment | 1 |
| 0000950170-25-066393 | 8 | 28 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by (used in) investing activities | 0 |
| 0000950170-25-066393 | 8 | 30 | CF | 0 | H | Proceeds From Issuance Of Convertible Preferred Stock | us-gaap/2024 | Proceeds from issuance of convertible preferred stock, net of issuance costs paid | 0 |
| 0000950170-25-066393 | 8 | 31 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from exercise of stock options | 0 |
| 0000950170-25-066393 | 8 | 32 | CF | 0 | H | Payments For Repurchase Of Unvested Restricted Common Stock | 0000950170-25-066393 | Repurchase of unvested restricted common stock | 1 |
| 0000950170-25-066393 | 8 | 33 | CF | 0 | H | Payments Of Financing Costs | us-gaap/2024 | Payment of deferred offering costs | 1 |
| 0000950170-25-066393 | 8 | 34 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0000950170-25-066393 | 8 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net increase in cash, cash equivalents, and restricted cash | 0 |
| 0000950170-25-066393 | 8 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents, and restricted cash at beginning of period | 0 |
| 0000950170-25-066393 | 8 | 37 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents, and restricted cash at end of period | 0 |
| 0000950170-25-066393 | 8 | 40 | CF | 0 | H | Settlement Of Series A Preferred Stock Tranche Right Liability | 0000950170-25-066393 | Settlement of preferred stock tranche right liability | 0 |
| 0000950170-25-066393 | 8 | 41 | CF | 0 | H | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2024 | Right-of-use assets obtained in exchange for operating lease liabilities | 0 |
| 0000950170-25-066393 | 8 | 42 | CF | 0 | H | Deferred Offering Costs | us-gaap/2024 | Deferred offering costs included in accounts payable and accrued expenses at period end | 0 |
| 0000950170-25-066393 | 8 | 43 | CF | 0 | H | Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | us-gaap/2024 | Purchases of property and equipment included in accounts payable and accrued expenses at period end | 0 |
| 0000950170-25-066393 | 8 | 45 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-066393 | 8 | 46 | CF | 0 | H | Restricted Cash Current | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-066393 | 8 | 47 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Total cash, cash equivalents and restricted cash shown in the statement of cash flows | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |